Cypress Prosorba Rheumatoid Arthritis Treatment Approvable - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Approval of Cypress Bioscience's Prosorba immunoadsorption column should be limited to treatment of moderate to severe rheumatoid arthritis in patients who have failed disease-modifying anti-rheumatic drugs (DMARDs), FDA's Gastroenterology and Urology Devices Panel concluded at its Oct. 29 meeting in Rockville, Maryland.